लैपाटिनिब के इंटरैक्शन

Avoid strong CYP3A4 inhibitors. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Avoid strong CYP3A4 inhibitors. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Avoid strong CYP3A4 inducers. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Avoid strong CYP3A4 inhibitors. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

Avoid strong CYP3A4 inhibitors. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Avoid strong CYP3A4 inhibitors. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Avoid strong CYP3A4 inducers. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

Avoid strong CYP3A4 inhibitors. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Avoid strong CYP3A4 inhibitors. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Avoid strong CYP3A4 inhibitors. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

Avoid strong CYP3A4 inhibitors. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Avoid strong CYP3A4 inhibitors. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Avoid strong CYP3A4 inhibitors. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

Avoid strong CYP3A4 inducers. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Avoid strong CYP3A4 inducers. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Avoid strong CYP3A4 inducers. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Avoid strong CYP3A4 inhibitors. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

In animal reproductive studies, administration of lapatinib to pregnant rats during the period of organogenesis and through lactation led to death of offspring within the first 4 days after birth at maternal exposures that were ≥ 3.3 times the human clinical exposure based on AUC following 1,250 mg dose of lapatinib plus capecitabine. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

P-glycoprotein The concomitant use of colchicine capsules and inhibitors of P-glycoprotein (e.g. clarithromycin, ketoconazole, cyclosporine, etc.) should be avoided due to the potential for serious and life-threatening toxicity [see Warnings and Precautions (5.3) and Clinical Pharmacology (12) ] . (कोल्चिसिन लेबल, दवाओं के इंटरैक्शन)

Avoid strong CYP3A4 inhibitors. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Avoid strong CYP3A4 inducers. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

Avoid strong CYP3A4 inducers. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Avoid strong CYP3A4 inhibitors. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Effect of Other Drugs on TALZENNA Effect of P-gp Inhibitors Breast Cancer Avoid coadministration of TALZENNA with the following P-gp inhibitors: itraconazole, amiodarone, carvedilol, clarithromycin, itraconazole, and verapamil. (टैलाज़ोपैरिब लेबल, दवाओं के इंटरैक्शन)

Avoid strong CYP3A4 inducers. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Avoid concomitant use HYCAMTIN capsules with P-gp inhibitors or BCRP inhibitors. (टोपोटेकन लेबल, दवाओं के इंटरैक्शन)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

Avoid strong CYP3A4 inhibitors. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Avoid strong CYP3A4 inhibitors. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

Avoid strong CYP3A4 inducers. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Avoid strong CYP3A4 inducers. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Avoid use of PRADAXA Capsules and P-gp inhibitors in patients with severe renal impairment (CrCl 15-30 mL/min) [see Drug Interactions (7.1) and Use in Specific Populations (8.6) ] . (डैबिगैट्रान लेबल, चेतावनियां और सावधानियां)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

Avoid strong CYP3A4 inhibitors. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Avoid strong CYP3A4 inhibitors. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Avoid strong CYP3A4 inducers. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Avoid strong CYP3A4 inducers. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (पाज़ोपैनिब लेबल, दवाओं के इंटरैक्शन)

Avoid strong CYP3A4 inhibitors. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Avoid strong CYP3A4 inhibitors. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Avoid strong CYP3A4 inhibitors. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Avoid strong CYP3A4 inducers. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

Avoid strong CYP3A4 inducers. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Avoid strong CYP3A4 inducers. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Avoid strong CYP3A4 inducers. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Avoid strong CYP3A4 inducers. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Avoid strong CYP3A4 inhibitors. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Avoid strong CYP3A4 inhibitors. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Avoid strong CYP3A4 inhibitors. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

Avoid strong CYP3A4 inducers. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Avoid strong CYP3A4 inducers. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Avoid strong CYP3A4 inducers. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Avoid strong CYP3A4 inhibitors. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Avoid strong CYP3A4 inhibitors. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

Avoid strong CYP3A4 inducers. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Avoid strong CYP3A4 inhibitors. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Avoid strong CYP3A4 inducers. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Avoid strong CYP3A4 inducers. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Avoid strong CYP3A4 inducers. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

• Potent Inhibitors of P-gp: Avoid another dose of NURTEC ODT within 48 hours when administered with a potent P-gp inhibitor. (रिमेजेपेंट लेबल, दवाओं के इंटरैक्शन)

Avoid strong CYP3A4 inhibitors. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

Avoid strong CYP3A4 inhibitors. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Avoid strong CYP3A4 inhibitors. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Avoid strong CYP3A4 inducers. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Therefore, the concomitant use of P-gp inhibitors or inducers should be avoided. (विन्क्रिस्टिन लेबल, दवाओं के इंटरैक्शन)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

Avoid strong CYP3A4 inhibitors. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Avoid strong CYP3A4 inhibitors. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Avoid strong CYP3A4 inhibitors. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

• Avoid concomitant use with strong CYP3A4/P-gp inducers or strong CYP3A4/P-gp inhibitors that decrease or increase sirolimus concentrations ( 7.4 , 12.3 ). (सिरोलिमस लेबल, दवाओं के इंटरैक्शन)

Avoid strong CYP3A4 inducers. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Avoid strong CYP3A4 inhibitors. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Avoid strong CYP3A4 inhibitors. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

Coadministration of VOSEVI with BCRP substrates (e.g., methotrexate, mitoxantrone, imatinib, irinotecan, lapatinib, rosuvastatin, sulfasalazine, topotecan) is not recommended [see Clinical Pharmacology (12.3) ]. (सोफोसबुविर और वेल्पाटासविर लेबल, दवाओं के इंटरैक्शन)

P-glycoprotein (P-gp) Inhibitors : Co-administration of P-gp inhibitors can increase afatinib exposure. (अफाटिनिब लेबल, दवाओं के इंटरैक्शन)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

P-gp Inhibitors Treatment of NVAF Based on clinical experience from the ENGAGE AF-TIMI 48 study, dose reduction in patients concomitantly receiving P-gp inhibitors resulted in edoxaban blood levels that were lower than in patients who were given the full dose. (एडोक्साबैन लेबल, दवाओं के इंटरैक्शन)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

Coadministration of DESCOVY with other drugs that inhibit P-gp and BCRP may increase the absorption and plasma concentration of TAF. (एमट्रिसिटाबिन और टेनोफोविर लेबल, दवाओं के इंटरैक्शन)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

…(e.g., atorvastatin, bosentan, ezetimibe, fluvastatin, glyburide, olmesartan, pitavastatin, pravastatin, rosuvastatin, repaglinide, rifampin, simvastatin acid, SN-38 [active metabolite of irinotecan], valsartan) or breast cancer resistance protein (BCRP) (e.g., imatinib, irinotecan, lapatinib, methotrexate, mitoxantrone, rosuvastatin, sulfasalazine, topotecan). (एल्ट्रोम्बोपैग लेबल, दवाओं के इंटरैक्शन)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

However, esomeprazole, a proton pump inhibitor, administered at a dose of 40 mg once daily for 7 days, did not result in a clinically meaningful reduction in lapatinib steady-state exposure. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

However, esomeprazole, a proton pump inhibitor, administered at a dose of 40 mg once daily for 7 days, did not result in a clinically meaningful reduction in lapatinib steady-state exposure. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

However, esomeprazole, a proton pump inhibitor, administered at a dose of 40 mg once daily for 7 days, did not result in a clinically meaningful reduction in lapatinib steady-state exposure. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

However, esomeprazole, a proton pump inhibitor, administered at a dose of 40 mg once daily for 7 days, did not result in a clinically meaningful reduction in lapatinib steady-state exposure. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

P-glycoprotein (P-gp) Inhibitors (e.g., amiodarone, captopril, cyclosporine, quercetin, quinidine, verapamil) Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse Reactions (6.1) ] . (नाल्डेमेडिन लेबल, दवाओं के इंटरैक्शन)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

However, esomeprazole, a proton pump inhibitor, administered at a dose of 40 mg once daily for 7 days, did not result in a clinically meaningful reduction in lapatinib steady-state exposure. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

However, esomeprazole, a proton pump inhibitor, administered at a dose of 40 mg once daily for 7 days, did not result in a clinically meaningful reduction in lapatinib steady-state exposure. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Paclitaxel : In cancer patients receiving TYKERB and paclitaxel (CYP2C8 and P-gp substrate), 24-hour systemic exposure (AUC) of paclitaxel was increased 23%. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

Concentrations of fidaxomicin and OP-1118 may also be decreased at the site of action (i.e., gastrointestinal tract) via P-gp inhibition; however, concomitant P-gp inhibitor use had no attributable effect on safety or treatment outcome of fidaxomicin-treated adult patients in controlled clinical trials. (फिडैक्सोमाइसिन लेबल, दवाओं के इंटरैक्शन)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

Midazolam : Following coadministration of TYKERB and midazolam (CYP3A4 substrate), 24-hour systemic exposure (AUC) of orally administered midazolam increased 45%, while 24-hour AUC of intravenously administered midazolam increased 22%. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

P-Glycoprotein (P-gp) Inhibitors Clinical Impact: The concomitant use of P-gp inhibitors can increase the exposure to morphine by two-fold and can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death. (मॉर्फिन लेबल, दवाओं के इंटरैक्शन)

• Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (रिफैक्सिमिन लेबल, चेतावनियां और सावधानियां)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

However, esomeprazole, a proton pump inhibitor, administered at a dose of 40 mg once daily for 7 days, did not result in a clinically meaningful reduction in lapatinib steady-state exposure. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

However, esomeprazole, a proton pump inhibitor, administered at a dose of 40 mg once daily for 7 days, did not result in a clinically meaningful reduction in lapatinib steady-state exposure. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

…Weak CYP3A4 inhibitors (such as alprazolam, amiodarone, amlodipine, atorvastatin, bicalutamide, cilostazol, cimetidine, cyclosporine, fluoxetine, fluvoxamine, ginkgo, goldenseal, isoniazid, lapatinib, nilotinib, pazopanib, ranitidine, ranolazine, ticagrelor, zileuton) can increase lomitapide exposure approximately 2-fold [see Clinical Pharmacology (12.3) ] . (लोमिटापाइड लेबल, दवाओं के इंटरैक्शन)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

Acid-Reducing Agents The aqueous solubility of lapatinib is pH dependent, with higher pH resulting in lower solubility. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Effects of Other Drugs on HALAVEN No drug-drug interactions are expected with CYP3A4 inhibitors, CYP3A4 inducers or P-glycoprotein (P-gp) inhibitors. (एरिबुलिन लेबल, दवाओं के इंटरैक्शन)

Dapagliflozin or dapagliflozin 3-O-glucuronide did not meaningfully inhibit P-gp, OCT2, OAT1, or OAT3 active transporters. (डैपाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Acid-Reducing Agents The aqueous solubility of lapatinib is pH dependent, with higher pH resulting in lower solubility. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Acid-Reducing Agents The aqueous solubility of lapatinib is pH dependent, with higher pH resulting in lower solubility. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Lenacapavir (LEN), a component of BIXLENVO, is a moderate inhibitor of CYP3A and a P-gp inhibitor. (बिक्टेग्राविर, एमट्रिसिटाबिन और टेनोफोविर एलाफेनामाइड लेबल, दवाओं के इंटरैक्शन)

Substrates and Inhibitors of P-glycoprotein It has been shown in vitro that mefloquine is a substrate and an inhibitor of P-glycoprotein. (मेफ्लोक्वीन लेबल, दवाओं के इंटरैक्शन)

Acid-Reducing Agents The aqueous solubility of lapatinib is pH dependent, with higher pH resulting in lower solubility. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Mechanism and Clinical Effect(s) Vepdegestrant is a P-gp inhibitor. (वेपडेजेस्ट्रेंट लेबल, दवाओं के इंटरैक्शन)

Strong P-glycoprotein (P-gp) Inhibitors In vitro studies indicated that silodosin is a P‑gp substrate. (सिलोडोसिन लेबल, दवाओं के इंटरैक्शन)

Acid-Reducing Agents The aqueous solubility of lapatinib is pH dependent, with higher pH resulting in lower solubility. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)